The Huntington Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Huntington Disease. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Huntington Disease and features dormant and discontinued products.

GlobalData tracks 186 drugs in development for Huntington Disease by 164 companies/universities/institutes. The top development phase for Huntington Disease is preclinical with 100 drugs in that stage. The Huntington Disease pipeline has 155 drugs in development by companies and 31 by universities/ institutes. Some of the companies in the Huntington Disease pipeline products market are: Medesis Pharma, U.S. National Institutes of Health and AFFiRiS.

The key targets in the Huntington Disease pipeline products market include Huntingtin (Huntington Disease Protein or HTT), Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN), and Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59).

The key mechanisms of action in the Huntington Disease pipeline product include Huntingtin (Huntington Disease Protein or HTT) Inhibitor with 29 drugs in Phase III. The Huntington Disease pipeline products include ten routes of administration with the top ROA being Oral and 14 key molecule types in the Huntington Disease pipeline products market including Small Molecule, and Gene Therapy.

Huntington Disease overview

Huntington’s disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

For a complete picture of Huntington Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.